Tags : Portfolio

Clinical Trials

Roche Highlights its Bispecific Antibody Portfolio Across a Range of

Shots: The company presented the new data of its T-cell engaging bispecific Abs, mosunetuzumab, glofitamab and cevostamab at ASH 2020, demonstrating encouraging activity across multiple types of blood cancer Roche divulges that its mosunetuzumab & glofitamab showed promising responses across multiple types of NHL, including R/R FL & DLBCL, reinforcing from the P-I/Ib GO29781 study […]Read More

M&A

UCB Acquires Handl Therapeutics to Augment its Gene Therapy Portfolio

Shots: The acquisition will bolster UCB’s pipeline program, capabilities, and platforms in the gene therapy space. The Handl Therapeutics will continue to be based in Leuven, Belgium while working closely with UCB’s international research teams In addition, the UCB collaborated with Lacerta to focus on CNS diseases, under which Lacera will lead research, preclinical activities, […]Read More

M&A

BMS to Acquire Forbius for its AVID200 to Expand its

Shots: Forbius will receive up front and milestones while BMS will acquire Forbius’s TGF-beta program, including the lead investigational asset, AVID200. The transaction is expected to be closed in Q4’20 Prior to closing, Forbius’ non-TGF-beta assets will be transferred to a newly formed private company, which will be retained by Forbius’ existing shareholders AVID200 is […]Read More

M&A

Bayer to Acquire KaNDy Therapeutics for Augmenting its Women’s Healthcare

Shots: KaNDy to receive $425M upfront, ~$450M milestones until launch followed by additional commercial milestones. The transaction is expected to be completed in Sept’2020 The acquisition will add KaNDy’s menopause drug to Bayer’s portfolio. KaNDy has published results of its NT-814 in P-IIb study that demonstrated positive results in mod. to sev. vasomotor symptoms due […]Read More

M&A MedTech

Olympus to Acquire Arc Medical Design for Expanding its Product

Shots: The acquisition will expand Olympus’ offerings in GI therapeutic devices and the development of advanced colonoscopy tools with the aim of improving early detection and treatment of CRC Olympus will obtain full rights to Arc Medical Design’s medical products and will convert its current exclusive distribution rights of Endocuff Vision to a full acquisition […]Read More

M&A

Kronos Bio to Acquire Gilead’s SYK Inhibitor Portfolio

Shots: Gilead to receive an up front in cash and convertible notes into Kronos equity, regulatory & commercial milestones along with royalties on sales of products emerges from the acquired programs Kronos to acquire the two clinical-phase assets along with the rest of Gilead’s portfolio of SYK inhibitors. The portfolio includes entospletinib, being evaluated in […]Read More

COVID-19 Pharma

Novartis Launches Zero Profit Portfolio for Symptomatic Treatment of COVID-19

Shots: Novartis will offer a portfolio of 15 generic and OTC medicines addressing the need of low- and lower-middle-income countries to treat patients with COVID-19 symptoms. The medicines will available governments, NGOs, and other institutional customers in up to 79 countries at zero-profit to support financially strained healthcare systems The Novartis’ COVID-19 portfolio aid to […]Read More

Pharma

Takeda to Divest a Portfolio of Select OTC and Non-Core

Shots: Takeda will divest a portfolio of ~18 select OTC and prescription pharmaceutical assets including Neosaldina, Nesina, and Dramin sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru to Hypera for a total value ~$825M. The transaction is expected to be close in H2’20 Takeda expects that its ~300 employees supporting the divested assets […]Read More

Pharma

Takeda to Divest its Portfolio of Select OTC and Non-Core

Shots: Takeda to receive ~$660M for divesting its 20 select prescription pharmaceutical and OTC products traded in Russia, Georgia, and several countries within the Commonwealth of Independent States. STADA to get rights, title, and interest to the products in the portfolio exclusive in these countries. The transaction is expected to close in Q4’19 Additionally, Takeda […]Read More